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Abstract
LnDOTA-tetraamide chelates (DOTA=1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)
have received considerable recent attention as a result of their potential to act as PARACEST
contrast agents for magnetic resonance imaging (MRI). Although PARACEST agents afford
several advantages over conventional contrast agents they suffer from substantially higher
detection limits; thus, improving the effectiveness of LnDOTA-tetraamide chelates is an important
goal. In this study we investigate the potential to extend conformational control of LnDOTA-type
ligands to those applicable to PARACEST. Furthermore, the question of whether δ- rather than α-
substitution of the pendant arms could be used to control the chelate coordination geometry is
addressed. Although δ-substitution does influence coordination geometry it does not afford
control. However, it can play an important role in governing the conformation of the amide
substituent relative to the chelate in such as way that suggests a PARACEST agent could be
designed that has detection limits at least as low as a conventional MRI contrast agent.
Keywords
conformational control; coordination modes; lanthanides; PARACEST agents; water exchange
Introduction
We have recently reported a method by which the coordination geometry adopted by Ln3+
chelates of DOTA-type ligands (DOTA=1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid) may be selected by appropriate substitution of the pendant arms and macrocyclic
ring.[1,2] LnDOTA chelates can interconvert between mono-capped square antiprism (SAP)
[**]NB-DOTA=2-(S)-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.
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and mono-capped twisted square antiprism (TSAP) coordination geometries either by a flip
in the conformation of the macrocyclic ring or a reorientation of the pendant arms.[3,4]
Substitution can effectively halt these intramolecular processes affording a single
coordination geometry.[1,2] The coordination geometry thus obtained is then determined by
the relative configuration of the substituents on the macrocyclic ring and the pendant arms;
when the configurations at these two locations are the same, a TSAP isomer results and
when they are opposed, a SAP isomer results.[1,2] The selection of coordination geometry in
this type of chelate is of interest since it may facilitate the design of more effective Gd3+-
based MRI contrast agents. TSAP isomers have consistently been found to have water
exchange rates that are 50–100-fold faster than those of SAP isomers,[5–7] a critical factor in
the behavior of Gd3+-based contrast agents. LnDOTA-tetraamide chelates exhibit a similar
coordination chemistry to DOTA chelates but much slower water proton exchange kinetics
as a result of the reduced electron density on the central metal ion. These slower exchange
rates have sparked interest in this class of chelate as potential PARACEST (paramagnetic
chemical exchange saturation transfer) agents.[8,9] Since slow exchange is desirable for
PARACEST, SAP isomers are generally preferred. It has been observed that LnDOTA-
tetraamides with more bulky amide substituents have a general preference for the SAP
coordination geometry, but recent results suggest that changes in the local environment, and
in particular the solvent, may cause changes in the coordination chemistry of LnDOTA-
tetraamide chelates.[10] Furthermore, addition of a second amide substituent seems to
increase the proportion of TSAP isomer present.[10] In light of these observations, we were
interested to know whether it was possible to selectively control the coordination geometry
of DOTA-tetraamide chelates through substitution in a manner analogous that used for
DOTA chelates. Of particular interest was the effect of introducing chirality into the δ-
position of an amide substituent of the pendant arm rather than in the α-position as
employed previously with DOTA chelates. The motivation for this approach is that α-
substitution necessarily involves a synthetic transformation at a chiral center, with all the
attendant problems. Control from the δ-position would eliminate these synthetic
complications. Chiral amide substituents have been reported to influence both the
orientation of pendant arms and configuration at phosphorus in triphosphinate-monoamide
chelates.[11] The question we sought to address in this work is whether, in DOTA-tetraamide
systems, this approach would not merely influence the orientation of the pendant arms but
define it.
Results and Discussion
EuDOTAM-Gly has been widely studied as a potential PARACEST agent[12–14] and, given
its potential suitability for use in vivo,[15,16] was therefore an ideal starting point for this
investigation. The conformation of the macrocyclic ring was
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controlled with the same nitrobenzyl substituent employed in our previous systems[1,2]—an
S- configuration conferring a (δδδδ) conformation upon the macrocyclic ring. Alanine was
substituted for glycine in the synthesis of the pendant arms. (R)-alanine ethyl ester and (S)-
alanine benzyl ester were used to prepare the two diastereoisomeric ligands S-RRRR-1 and
S-SSSS-1 (Scheme 1). In each case the alanine ester was condensed with bromoacetyl
bromide in CH2Cl2 with K2CO3 as base. The resulting bromoacetamides were then used to
alkylate the S-2-nitrobenzyl cyclen. Ester cleavage—saponification for the ethyl esters and
BCl3 in CH2Cl2 in the case of benzyl esters[17]—afforded S-RRRR-1 and S-SSSS-1. The
Ln3+ chelates were then prepared from the corresponding Ln3+ triflate in water at pH 6 and
purified by preparative RP-HPLC (C18) to afford each chelate in its protonated form.
The coordination geometry of DOTA and DOTA-tetraamide type chelates are known to be
strongly affected by the ionic radius of the Ln3+ ion. A preference for the TSAP geometry is
observed for earlier (larger) Ln3+ ions, switching to the SAP geometry as the ionic radius
decreases across the series.[18,19] To account for the effect of ionic radius the Pr3+, Eu3+, and
Yb3+ chelates of each ligand were prepared and examined by 1H NMR spectroscopy. In the
case of Pr3+, only one coordination geometry could be detected for each chelate (Figure 1),
indicating that, as expected, the S-RRRR-isomer adopts the Λ(δδδδ) SAP coordination
geometry and the S-SSSS-isomer is in the Δ(δδδδ) TSAP conformation, exclusively.
Reducing the ionic radius of the Ln3+ ion (Pr3+ →Eu3+→Yb3+) was found to have no effect
on the chelates of S-RRRR-1, which were found to exist in only one coordination geometry
(the Λ(δδδδ) conformation) across the lanthanide series (Figure 1, 2, and 3). In contrast, the
chelates of S-SSSS-1 were found to be profoundly affected by changing the ionic radius of
the Ln3+ ion with increasing amounts of chelate in a SAP coordination geometry being
discernable in the NMR spectrum of the Eu3+ and Yb3+ chelates (Figure 2 and Figure 3).
For EuS-SSSS-1 the amount of SAP isomer observed is quite small, approximately 5%, but
for YbS-SSSS-1 the amount increases to almost 50%. It is also notable that considerable line
broadening can be observed in the spectrum of the TSAP isomer of EuS-SSSS-1, but not the
SAP isomer. The line broadening is also not observed in the corresponding Yb3+ chelate.
The origin of this effect remains obscure but perhaps relates to an increase in internal
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vibrational or torsional motions in the ligand, shortening T2, as it attempts, but fails, to
overcome the energy barrier associated with isomeric exchange.
For a chelate of S-SSSS-1 to adopt a SAP coordination geometry, either the macrocyclic ring
or the pendant arms must adopt a conformation that opposes the configuration of the chiral
center located on that group. A flip in the conformation of the macrocyclic ring would place
the nitrobenzyl substituent in an axial position, substantially increasing the torsional strain in
the system and may be considered highly unlikely. Rather it seems that the SAP form arises
from the pendant arms rotating into the unexpected conformation (Λ rather than Δ for the S-
SSSS-isomer).[20] In an α-substituted system, torsional strain is minimized by placing the
substituent as far from the metal (trans- across the N—Cα bond) as possible (Figure 4). This
determines the orientation of the pendant arms. The origins of control observed in some δ-
substituted systems remain ambiguous; however, a survey of crystallographic data on related
systems suggests that a preferred conformation exists.[11,21–27] It appears that the lowest
energy conformation points the hydrogen of the chiral center towards the metal ion, the
bulkiest substituent is then placed in a pseudo-equatorial position relative to the chelate
(Figure 4). This can occur only if the pendant arms are orientated appropriately: Λ for an R-
configuration, Δ for S-configuration. If the arms rotate and adopt the opposite orientation,
then the bulky substituent is placed in a pseudo-axial position that is presumably higher in
energy (Figure 4). Examples of this situation in the crystallographic literature suggest that
this occurs primarily when a second factor forces the arms into the orientation that opposes
the configuration of the chiral substituent.[21] It seems likely that the decrease in ionic
radius, and perhaps the associated increase in charge density, contributes to an increase in
this second factor for LnS-SSSS-1 chelates as one passes along the Ln3+ series. All
LnDOTAM-Gly chelates exhibit an exclusive preference for the SAP geometry and
although the reasons for this are unclear, it does explain why no TSAP isomer was observed
for any of the LnS-RRRR-1 chelates, even for Pr3+ which often exhibits a preference for this
co-ordination geometry. This phenomenon, which drives LnDOTAM-Gly chelates into
exclusively SAP geometries, is presumably the same as that which results in SAP isomers
being observed for the LnS-SSSS-1 chelates. The SAP isomer that is observed would be the
same Λ(δδδδ) conformation observed for the LnS-RRRR-1 chelates but with one significant
difference: the carboxylate substituent must occupy a pseudo-axial rather than a pseudo-
equatorial position.
Although the substitution of the δ-position does not afford control over the coordination
geometry in LnS-SSSS-1 chelates, preliminary results suggest that the intramolecular
exchange processes between the two coordination geometries have been “frozen out”. No
evidence of exchange could be detected by EXSY or by saturation transfer experiments on
the highly shifted acetate peaks of YbS-SSSS-1, suggesting that the two isomers (SAP and
TSAP) are either not in exchange or exchange so slowly that the process cannot be detected
by these techniques.
From the point of view of PARACEST agent design, chelates that adopt a SAP coordination
geometry are preferred because, in general, they possess slower water proton exchange
kinetics. The unexpected appearance of a second conformer of the SAP coordination
geometry, that adopted by EuS-SSSS-1, afforded a unique opportunity to examine how the
orientation of the carboxylate group affects CEST. NMR samples were prepared to compare
the CEST of EuS-RRRR-1 with that of EuS-SSSS-1 at 1) the same overall concentration of
chelate (274 μm) and 2) the same concentration of SAP isomer (13.7 μm) (Figure 5). CEST
peaks at approximately + 50 ppm were observed for both chelates: 52 ppm for EuS-RRRR-1
and 49 ppm for EuS-SSSS-1, consistent with CEST arising from a SAP coordination
geometry in each case. When the overall chelate concentration ([Eu3+]) is the same, the
magnitude of CEST arising from EuS-RRRR-1 is approximately threefold greater than that
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of EuS-SSSS-1 (Figure 5, open symbols), but the SAP isomer constitutes only 1/20 of the
EuS-SSSS-1 chelate. When the concentrations of the SAP isomer in each sample were
normalized ([SAP]=13.7 μm), no CEST was observed from Eu-S-RRRR-1, whereas EuS-
SSSS-1 produces a change in bulk water signal of approximately 10% (Figure 5, circles).
Clearly the SAP isomer of EuS-SSSS-1 is a substantially more effective PARACEST agent
than that of EuS-RRRR-1.
To better understand the difference between these two SAP isomers these CEST data were
quantitatively analyzed. In general CEST spectra may be fitted to the Bloch equation
modified for exchange,[28] however, a reasonable fit between this model and the data for
EuS-SSSS-1 could not be obtained when the concentration of water shifted to +49 ppm was
the same as that of the SAP isomer (see Figure S2 in the Supporting Information). The water
proton residence lifetime (τMH) for the SAP isomer of each chelate was therefore
determined independently by the so-called ω-method’,[29] affording values of τMH=116 μs
(EuS-RRRR-1) and 65 μs (EuS-SSSS-1) (Figure 6). These values could then be applied to
modeling the data to the modified Bloch equations. The spectrum of Eu-S-RRRR-1 fitted to
theory satisfactorily (Figure 5), however, the spectrum of EuS-SSSS-1 continued to prove
difficult to fit. A satisfactory fit for these data could only be obtained when the
concentration of protons in the highly shifted pool (+49 ppm) was allowed to increase
beyond the concentration of the SAP isomer. When the concentration of water molecule in
this pool was 3.7 times that of the SAP isomer a good fit was obtained suggesting that
between two and three additional water molecules may be present in the highly shifted pool
of EuS-SSSS-1 (Figure 5). These additional water molecules must be closely held and highly
shifted by Eu3+, although perhaps not so highly shifted as the coordinated water, which may
account for the slightly smaller shift of the CEST peak in this chelate. These additional
water protons would certainly explain why the SAP isomer of EuS-SSSS-1 is a much more
effective PARACEST agent than EuS-RRRR-1.
Although two conformational isomers (pseudo-axial/equatorial) have been postulated
previously[11] the two diastereoisomeric chelates of Eu1 have for the first time afforded an
opportunity to examine the CEST properties of each. The S-SSSS (pseudo-axial) isomer is a
significantly more effective PARACEST agent possibly because it closely holds more than
one water molecule in a highly shifted pool. In such a situation the value of τMH reflects all
protons in this pool, it is therefore difficult to understand exactly how the exchange kinetics
of these chelates modulate CEST.
These results demonstrate, for the first time, that it may be possible to design PARACEST
agents that have detection limits for MRI comparable to current MRI contrast agents. In
Figure 4 EuS-SSSS-1 generates about 10% CEST at an overall chelate concentration of
0.274 mM. However, only about 5% of the chelate is responsible for this CEST so the active
concentration is just 13.7 μm, but these measurements are in only 10% water in acetonitrile.
Assuming a linear relationship between CEST and concentration (which is approximately
true at very low concentrations),[30] 137 μm could generate 10% CEST. A change in water
signal intensity of only about 3% is required to observe contrast changes in an MR image, so
just 46 μm of the SAP isomer of EuS-SSSS-1 should afford an MRI detectable level of CEST
in pure water.
Although these measurements were performed by using admittedly high B1 powers
(upwards of 1 kHz) there is scope for B1 to be substantially reduced before the detection
limit of the active form of this agent exceeds 0.1 mM, the typical dose of a clinical MRI
contrast agent (0.1 mmol kg−1). Clearly further experimentation is required to better
understand the potential of the type of system for PARACEST design. Nonetheless, these
preliminary data do suggest that attending to the coordination chemistry of LnDOTA-
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All solvents and reagents were purchased from commercial sources and used as received
except where noted. ‘Water’ refers to deionized water with a resistivity of <18.2 MΩcm. 1H
and 13C NMR spectra were acquired on a JOEL Eclipse 270 spectrometer operating at
270.17 and 67.94 MHz, respectively. CEST spectra were acquired on a Bruker Avance IIa
400 spectrometer operating at 400.13 MHz. Infrared spectra were recorded on a Nicolet
Avatar 360 FTIR spectrophotometer. Melting points were recorded on a Fisher–Johns
melting point apparatus and are uncorrected. RP-HPLC purification was performed on a
Waters δ-prep HPLC system using a 30×250 mm Phenomenex Luna C18(2) column. In all
cases ligands were purified by eluting for 5 min of 100% water (0.037% HCl) followed by a
linear gradient over 35 min to 40% acetonitrile and 60% water (0.037% HCl) at a flow rate
of 30 mL min−1. Chelates were purified by eluting for 5 min with 100% water (0.037%
HCl) followed by a linear gradient over 35 min to 10% acetonitrile and 90% water (0.037%
HCl) at a flow rate of 30 mL min−1. Elution of products was monitored by UV absorbance
at 210 and 270 nm.
(R)-N-(Ethyl-2-propionate) bromoacetamide (2)
To a solution of bromoacetyl bromide (2.40 mL, 26.3 mmol) in dichloromethane (100 mL)
was added potassium carbonate (6.04 g, 43.8 mmol) and the resulting suspension was cooled
to 0°C. A solution of (R)-alanine ethyl ester (2.57 g, 21.9 mmol) in dichloromethane (50
mL) was added dropwise over a period of 20 min. The mixture was stirred for a further 30
min at 0°C and 18 more hours at room temperature. Water (30 mL) was added cautiously
and the two layers separated. The aqueous phase was extracted with dichloromethane (50
mL), the organic phases were combined, dried (Na2SO4), and the solvents removed under
reduced pressure. The residue was taken up into a minimum of dichloromethane and
recrystallized by addition ethyl ether and hexanes at −20°C to afford a colorless solid (1.98
g 38%). M.p. 66–67°C; 1H NMR (CDCl3, 270 MHz): δ=7.13 (s br, 1H, NH), 4.52
(dq, 3JHH=7 Hz, 3JHH=7 Hz, 1H, NHCHCH3), 4.26 (q, 3JHH=8 Hz, 2H, OCH2CH3), 3.82 (s,
2H, BrCH2), 1.45 (d, 3JHH=7 Hz, 3H, CHCH3), 1.27 ppm (t, 3JHH=8 Hz, 3H, CH2CH3); 13C
NMR (CDCl3, 68 MHz): δ=171.6 (C=O), 164.5 (NHC=O), 60.1 (OCH2), 47.8 (BrCH2),
27.6 (CH), 17.3 (OCH2CH3), 13.4 ppm (CHCH3); νmax (KBr disc)=3743 (NH), 1738 (CO2),
1647 cm−1 (NHC=O); m/z (ESMS EI−): 236 (100%, [M−H+]−), appropriate isotope patterns
were observed.
(S)-N-(Benzyl-2-propionate) bromoacetamide (3)
L-Alanine benzyl ester hydrochloride (4.0 g, 18.5 mmol) was dissolved in water (20 mL) and
sodium carbonate added until the solution pH exceeded 12. The solution was then extracted
with dichloromethane (2×200 mL). The organic extracts were combined, dried (Na2SO4),
and the solvents were removed under reduced pressure. The residue was taken up into
dichloromethane (50 mL) and the resulting solution added dropwise to a solution of
bromoacetyl bromide (2.0 mL, 22.2 mmol) in dichloromethane (100 mL) containing
potassium carbonate (5.11 g, 37.0 mmol) and cooled to 0°C in an ice-bath. Addition was
carried out over a period of 20 min and the reaction stirred for a further 30 min at 0°C. The
reaction mixture was allowed to warm to room temperature and stirred for 18 h at ambient
temperature. Water (30 mL) was added cautiously and the two layers separated. The
aqueous phase was extracted with dichloromethane (50 mL), the organic phases were
combined, dried (Na2SO4), and the solvents removed under reduced pressure. The residue
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was taken up into a minimum of dichloromethane and recrystallized by addition ethyl ether
and hexanes at −20°C to afford a colorless solid (3.44 g, 62%). M.p. 59–61°C; 1H NMR
(CDCl3, 270 MHz): δ=7.34 (m, 5H, Ar), 7.06 (s br, 1H, NH), 5.12 (d, 2JHH=10 Hz, 1H, aa’
system, ArCH2) 5.11 (d, 2JHH=10 Hz, 1H, aa system, ArCH2), 4.6 (dq, 3JHH=7 Hz, 3JHH=7
Hz, 1H, NHCHCH3), 3.82 (s, 2H, BrCH2), 1.47 ppm (d, 3JHH=7 Hz, 3H, CH3); 13C NMR
(CDCl3, 68 MHz): δ=172.4 (CO2), 165.6 (NHC=O), 135.2 (Ar), 129.9 (Ar), 129.1 (Ar),
128.4 (Ar), 67.7 (ArCH2), 49.2 (BrCH2), 29.4 (CH), 18.7 ppm (CH3); νmax (KBr disc): 1734
(CO2), 1717 (CO2), 1653 cm−1 (NHC=O); m/z (ESMS EI−): 298 (100%, [M−H+]−) an
appropriate isotope pattern was observed.
(1R, 4R, 7R, 10R)-δ, δ′, δ″, δ‴-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10-
tetraazacyclododecane]-1,4,7,10-tetraacetateacetamide (H4S-RRRR-1)
2-S-(p-Nitrobenzyl) cyclen (150 mg, 0.49 mmol) and the bromoacetamide 2 (581 mg, 2.44
mmol) were dissolved in acetonitrile (30 mL), and potassium carbonate (337 mg, 2.44
mmol) was added. The resulting suspension was heated under reflux with stirring for seven
days. The solvents were then removed under reduced pressure and the residue taken up into
water (20 mL) and dichloromethane (100 mL). The two layers were separated and the
aqueous phase extracted with dichloromethane (2×50 mL). The organic phases were
combined, dried (Na2SO4), and the solvents removed under reduced pressure. The residue
was taken up into tetrahydrofuran (5 mL) and water (10 mL) and a 1M sodium hydroxide
solution (2.4 mL) added. The resulting monophasic solution was heated to 60°C for 48 h.
The solvents were removed under reduced pressure and the residue taken up into water and
the pH adjusted to 7 with HCl prior to RP-HPLC purification. After lyophilization of the
solvents the dihydrochloride salt of title compound was obtained as a colorless solid (147
mg, 30%). RT=27.79 min; m.p.>170°C; 1H NMR (D2O, 270 MHz): δ=8.11 (d, 3JHH=8 Hz,
2H, Ar), 7.40 (d, 3JHH=8 Hz, 2H, Ar), 2.66–4.43 (m br, 29H, ring NCH2, CH2C=O, CH2Ar,
CHCH3), 1.31 ppm (m, 12H, CHCH3); m/z (ESMS EI+): 824 (100%, [M+H+]); νmax (iTR):
3023 (NH), 1733 (CO2), 1656 (C=ONH), 1546, 1519, 1454, 1346, 1210, 1157, 943, 735
cm−1.
(1S, 4S, 7S, 10S)-δ, δ′, δ″, δ‴-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10-
tetraazacyclododecane]-1,4,7,10-tetraacetateacetamide (H4S-SSSS-1)
2-S-(p-Nitrobenzyl) cyclen (250 mg, 0.81 mmol) and the bromoacetamide 3 (1.22 g, 4.07
mmol) were dissolved in acetonitrile (30 mL), and potassium carbonate (562 mg, 4.07
mmol) was added. The resulting suspension was heated under reflux with stirring for seven
days. The solvents were then removed under reduced pressure and the residue taken up into
water (20 mL) and dichloromethane (100 mL). The two layers were separated and the
aqueous phase extracted with dichloromethane (2×50 mL). The organic phases were
combined, dried (Na2SO4), and the solvents removed under reduced pressure. The residue
was taken up into dry chloroform (10 mL); 5 mL of the resulting solution was transferred to
a reaction flask which was purged with argon. The reaction mixture was cooled to −10°C in
a salt/ice-bath, and a 1M solution of BCl3 in dichloromethane (1.6 mL) was added. After
addition the reaction mixture was allowed to warm to ambient temperature and was then
stirred for 14 h. Water (2 mL) was added dropwise to quench the reaction, followed by 1M
HCl (8 mL) and the ligand was extracted into the aqueous phase. The ligand solution was
used directly to purify the title compound by RP-HPLC. After lyophilization of the solvents
the dihydrochloride salt of title compound was obtained as a colorless solid (78.4 mg, 20%).
RT=25.94 min; m.p.>170°C; 1H NMR (D2O, 270 MHz): δ=8.21 (d, 3JHH=8 Hz, 2H, Ar),
7.42 (d, 3JHH=8 Hz, 2H, Ar), 2.72–4.31 (m br, 29H, ring NCH2, CH2C=O, CH2Ar,
CHCH3), 1.28 ppm (m, 12H, CHCH3); m/z (ESMS EI+): 824 (100%, [M+H+]+); νmax
(iTR): 3169 (NH), 1727 (CO2), 1617 (C=ONH), 1455, 1346, 1253, 1155, 957, 821, 751
cm−1.
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General procedure for the preparation of Ln3+ chelates
Europium triflate (15 mg, 24.6 mmol) and 1 (20 mg, 22.3 mmol) were dissolved in water
and the pH adjusted to 6 by addition of NaOH (1M aqueous solution). The resulting solution
was heated at 60 C for 24 h and then allowed to cool to room temperature. After filtration
through a 20 mm syringe filter the reaction mixed was injected directly onto a preparative
HPLC system for purification. Chelates were obtained by lyophilization of the fraction
containing the major reaction product.
Praseodymium(III) (1R, 4R, 7R, 10R)-δ, δ′, δ″, δ‴-Tetramethyl-[2-(S)-(p-
nitrobenzyl)-1,4,7,10-tetraazacyclododecane]-1,4,7,10-tetraacetateacetamide (HPrS-
RRRR-1)
RT=30.20 min; m/z (ESMS EI−): 963 (100%, [M−H+]−) an appropriate isotope pattern was
observed.
Europium(III) (1R, 4R, 7R, 10R)-δ, δ′, δ″, δ‴-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10-
tetraazacyclododecane]-1,4,7,10-tetraacetateacetamide (HEuS-RRRR-1)
RT=24.96 min; m/z (ESMS EI−): 975 (100%, [M−H+]−) an appropriate isotope pattern was
observed.
Ytterbium(III) (1R, 4R, 7R, 10R)-δ, δ′, δ″, δ‴-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10-
tetraazacyclododecane]-1,4,7,10-tetraacetateacetamide (HYbS-RRRR-1)
RT=31.31 min; m/z (ESMS EI−): 996 (100%, [M−H+]−) an appropriate isotope pattern was
observed.
Praseodymium(III) (1S, 4S, 7S, 10S)-δ, δ′, δ″, δ‴-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10-
tetraazacyclododecane]-1,4,7,10-tetraacetateacetamide (HPrS-SSSS-1)
RT=25.33 min; m/z (ESMS EI−): 963 (100%, [M−H+]−) an appropriate isotope pattern was
observed.
Europium(III) (1S, 4S, 7S, 10S)-δ, δ′, δ″, δ‴-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10-
tetraazacyclododecane]-1,4,7,10-tetraacetateacetamide (HEuS-SSSS-1)
RT=30.24 min; m/z (ESMS EI−): 975 (100%, [M−H+]−) an appropriate isotope pattern was
observed.
Ytterbium(III) (1S, 4S, 7S, 10S)-δ, δ′, δ″, δ‴-Tetramethyl-[2-(S)-(p-nitrobenzyl)-1,4,7,10-
tetraazacyclododecane]-1,4,7,10-tetraacetateacetamide (HYbS-SSSS-1)
RT=20.45 min; m/z (ESMS EI−): 996 (100%, [M−H+]−) an appropriate isotope pattern was
observed.
CEST fitting
CEST spectra were recorded at six different B1 powers for each chelate: 42.7 μT, 36.3 μT,
34.3 μT, 30.1 μT, 27.4 μT, and 24.3 μT (see Figure S1 in the Supporting Information). The
water proton exchange kinetics for each SAP isomer were determined by plotting the
magnetization at the CEST peak minimum as a function of the initial magnetization (MZ/
(M0−MZ)) against the reciprocal of the square of the B1 power expressed in rad s−1 (1 ω2)
(Figure 6). The data were then fitted by using linear regression analysis and the intercept of
the line with the x axis provides the water exchange rate directly.[29]
The CEST spectra were then fitted to the Bloch equations modified for exchange as
previously described.[28] A 2-pool model was used to fit the data for EuS-RRRR-1
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representing the bulk water pool, the bound or shifted water pool. The inclusion of a pool for
the amide protons was found not to affect the fitting and therefore excluded from the all
fitting models. A 3-pool model was used to fit the data for EuS-RRRR-1 representing the
bulk water, the bound water or shifted water associated with the SAP isomer and the bound
or shifted water associated with the TSAP isomer.
The pre-saturation power (B1) was held fixed during fitting. The water proton exchange
lifetime (τMH) was constrained to lie within 10% of the value determined by the ω-fitting. In
initial fittings the concentration of each pool was deconstrained to reflect the confidence
level of the concentration determination. T1 values for the bulk water pool were determined
experimentally using an inversion recovery pulse sequence and held fixed during fitting. T1
values for the other pools could not be determined by direct measurement owing to the low
chelate concentrations of each sample. The T1s of these pools and all T2 values were
allowed to float over the range of values previously found in CEST fitting routines in
EuDOTA-tetramide chelates.[31] The value of τMH for the TSAP isomer, which does appear
to influence the shape of the direct saturation peak at 0 ppm (witness the downfield edge of
the peak), was constrained to have a ratio of between 1/40 and 1/60 of the τMH value of the
SAP isomer. This ratio is consistent with previously reported behavioral patterns in this type
of chelate.
Fitting the CEST data acquired at B1=1282.8 Hz afforded a good fit to the data for EuS-
RRRR-1. However, a suitable fit to the S-SSSS-isomer could not be obtained when the
concentration was constrained as described (see Figure S2 in the Supporting Information).
Only when the concentration of the highly shifted pool is allowed to float and fit to values
3.7 times higher than the 13.7 μm chelate concentration is an adequate fit achieved.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The preparation of the two diastereoisomeric ligands 1. Reagents and conditions: S-RRRR-1,
R=Et: i. BrCH2COBr/K2CO3/CH2Cl2/0°C; ii. S-NB-cyclen/K2CO3/MeCN/60°C; iii. NaOH/
H2O/THF; iv. HCl: S-SSSS-1, R=Bn: i. BrCH2COBr/K2CO3/CH2Cl2/0°C; ii. S-NB-cyclen/
K2CO3/MeCN/60°C; iii. BCl3/CH2Cl2/THF; iv. H2O.
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The 1H NMR spectra of PrS-RRRR-1 (top) PrS-SSSS-1 (bottom) and recorded at 400 MHz
and 300 K in D2O at pD 4. The four highly shifted peaks between δ=−28 and −35 ppm (top)
and δ=−10 and −16 ppm (bottom), are characteristic of the shifts of the axS protons in SAP
and TSAP isomers of PrDOTA-tetraamide chelates, respectively.
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The 1H NMR spectra of EuS-RRRR-1 (top), EuS-SSSS-1 (bottom) recorded at 400 MHz and
300 K in D2O at pD 4. The four shifted peaks between 22 and 27 ppm (both spectra) and 7
and 10 ppm (bottom) are typical of those observed for the SAP and TSAP isomers of
EuDOTA-tetraamide chelates, respectively.
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The 1H NMR spectra of YbS-RRRR-1 (top), YbS-SSSS-1 (bottom) recorded at 400 MHz and
275 K in D2O at pD 4. The four shifted peaks between 82 and 103 ppm (both spectra) and
20 and 35 ppm (bottom) are typical of those observed for the SAP and TSAP isomers of
YbDOTA-tetraamide chelates, respectively.
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The orientation of chiral pendant arms and how they are affected by α- (top) and δ-
substitution (bottom), in each case the configuration at carbon is R.
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CEST spectra of solutions of EuS-RRRR-1 ([Eu3+]=[SAP]=274 μM open diamonds;
[Eu3+]=[SAP]=13.7 μM closed circles) and EuS-SSSS-1 ([Eu3+]=274 μM, [SAP]=13.7 μM open
circles) in CD3CN (10% H2O) recorded at 400 MHz; 298 K; irr. time=10 s; B1=30 μT.
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The ω-plots of EuS-RRRR-1 (filled circles) and EuS-SSSS-1 (open diamonds), data taken
from the CEST spectra in Figure S1 in the Supporting Information. The difference in slope
of the two lines can be attributed to the difference in SAP isomer concentration between the
two samples. The water proton residence lifetimes are afforded by the intercept of the x axis.
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